Cover Image
市場調查報告書

C型肝炎:流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

Hepatitis C: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365202
出版日期 內容資訊 英文 366 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎:流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 Hepatitis C: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 366 Pages
簡介

210億美元規模的C型肝炎治療藥的市場,2016年之後,由於新加入經營者的價格競爭加劇和患者人口的減少等影響,預計減少收益。

本報告提供C型肝炎治療藥趨勢調查,市場定義和概要,疾病與定義診斷,目前治療選擇,處方趨勢,未滿足需求,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:C型肝炎

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Daklinza (daclatasvir)
  • glecaprevir/pibrentasvir
  • Harvoni (sofosbuvir/ledipasvir)
  • Olysio (simeprevir)
  • sofosbuvir/velpatasvir
  • sofosbuvir/velpatasvir/GS-9857
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir)
  • Technivie (paritaprevir/ritonavir/ombitasvir)
  • Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
  • Zepatier (grazoprevir/elbasvir)
  • 一次調查技術

治療方法:C型肝炎

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:美國、日本、歐盟5國的C型肝炎

  • 摘要整理
  • 疾病的背景
  • 資訊來源、分析方法
  • 預測
  • 流行病學者的見解
  • 優勢、規定

上市藥:C型肝炎

  • 摘要整理
  • 產品概要
  • 產品簡介:Daklinza
  • 產品簡介:Harvoni
  • 產品簡介:Olysio
  • 產品簡介:Sovaldi
  • 產品簡介:Sunvepra
  • 產品簡介:Viekira Pak
  • 產品簡介:Zepatier

開發平台:C型肝炎

  • 摘要整理
  • 臨床實驗平台概要
  • 開發初期的市場機會
  • 產品簡介 (開發後期):glecaprevir/pibrentasvir
  • 產品簡介 (開發後期):sofosbuvir/velpatasvir
  • 產品簡介 (開發後期):sofosbuvir/velpatasvir/GS-9857

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5260

The $21bn hepatitis C market is expected to undergo a net decline from 2016 as new entrants intensify pricing competition and patient numbers are exhausted from the early 2020s.

This report addresses the following questions:

  • To what extent will the launch of Merck & Co's Zepatier at a discounted price affect sales of Gilead's and AbbVie's regimens?
  • With cure rates approaching 100% in many patient groups, when will high cure rates begin to offset the influx of newly diagnosed patients seeking treatment in each market?
  • Which regimens currently dominate the treatment algorithm for each genotype of infection and why?
  • How have recent trial data presented at the2016 International Liver Congress affected the commercial potential of next-generation oral regimens?
  • How do pipeline pan-genotypic regimens compare and how are companies attempting to differentiate their products?

TABLE OF CONTENTS

FORECAST: HEPATITIS C

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Daklinza (daclatasvir)
  • 5. glecaprevir/pibrentasvir
  • 6. Harvoni (sofosbuvir/ledipasvir)
  • 7. Olysio (simeprevir)
  • 8. sofosbuvir/velpatasvir
  • 9. sofosbuvir/velpatasvir/GS-9857
  • 10. Sovaldi (sofosbuvir)
  • 11. Sunvepra (asunaprevir)
  • 12. Technivie (paritaprevir/ritonavir/ombitasvir)
  • 13. Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
  • 14. Zepatier (grazoprevir/elbasvir)
  • 15. Primary Research Methodology

TREATMENT: HEPATITIS C

  • 16. Executive Summary
  • 17. Primary Research Methodology
  • 18. Disease Definition and Diagnosis
  • 19. Patient Segmentation
  • 20. Current Treatment Options
  • 21. Country Treatment Trees
  • 22. Prescribing Trends
  • 23. Unmet Needs in Hepatitis C

EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU

  • 24. Executive Summary
  • 25. Disease Overview
  • 26. Sources and Methodology
  • 27. Forecast
  • 28. Epidemiologist Insight,
  • 29. Strengths and Limitations
  • 30. Appendix

MARKETED DRUGS: HEPATITIS C

  • 31. Executive Summary
  • 32. Product profile: Daklinza
  • 33. Product profile: Harvoni
  • 34. Product profile: Olysio
  • 35. Product profile: Sovaldi
  • 36. Product profile: Sunvepra
  • 37. Product profile: Viekira Pak
  • 38. Product profile: Zepatier

PIPELINE: HEPATITIS C

  • 39. Executive Summary
  • 40. Clinical Pipeline Overview
  • 41. Early-Phase Opportunities
  • 42. Product profile (late stage): glecaprevir/pibrentasvir
  • 43. Product profile (late stage): sofosbuvir/velpatasvir
  • 44. Product profile (late stage): sofosbuvir/velpatasvir/GS-9857
Back to Top